Visão geral da empresa
A clinical-stage biopharmaceutical entity, Praxis Precision Medicines, Inc., focuses its operational efforts on developing advanced therapies designed to address central nervous system disorders that are characterized by a specific neuronal excitation-inhibition imbalance within the United States market. The company operates within the broader Healthcare sector, specifically targeting the specialized Biotechnology industry, which implies a high reliance on research and development phases before potential commercial product launches. Its current scale is defined by a market capitalization of $8.92 billion, a total employee count of 168, and reported annual revenue figures that are currently unavailable for the trailing twelve months. The combination of a substantial market cap of $8.92 billion with a workforce of only 168 employees and unlisted revenue suggests a capital-intensive enterprise where valuation is heavily influenced by pipeline potential rather than established cash-generating operations typical of mature pharmaceutical firms.
Saúde financeira
Praxis Precision Medicines reports a net income of $-303,268,000 for the trailing twelve months, while its EBITDA stands at $-326,057,984, indicating significant operating expenses that exceed current revenue streams, as revenue data is not available for this period. The gap between the reported net loss and the EBITDA figure highlights the extent of non-operating costs and interest expenses impacting the bottom line, though the absence of revenue data makes a precise cost-to-revenue efficiency analysis impossible at this stage. The company's free cash flow is recorded at $-146,253,744, which reflects a capital-intensive business model where substantial cash outflows are required for clinical trials and development activities rather than generating immediate liquidity from sales. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are listed at 0.0%, a figure typical for clinical-stage biotechs that have not yet achieved commercial product sales to generate gross profit or operating earnings. Regarding balance sheet stability, the company holds $599.33 million in cash against a total debt obligation of $110,000, resulting in a debt-to-equity ratio of 0.01 that signifies an extremely conservative leverage profile with negligible debt burden. This liquidity position is further reinforced by a current ratio of 10.22, which indicates robust short-term liquidity and a substantial buffer to cover current liabilities without immediate distress. Finally, the Return on Equity is -45.8% and the Return on Assets is -28.7%, metrics that mathematically reflect the current investment phase where capital is being deployed to build value rather than returning it through profits, rather than indicating management ineffectiveness in a standard operational context.
Avaliação de valorização
The company's valuation metrics present a complex picture with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -37.04, the latter implying that future earnings estimates are expected to remain negative for the foreseeable future due to ongoing development costs. The Price to Book ratio stands at 9.19, indicating that the market prices the company at a significant premium over its tangible book value, a common characteristic for biotechnology firms where intangible assets and intellectual property drive value rather than physical assets. Alternative valuation metrics include a Price to Sales ratio of N/A and an EV/EBITDA of -25.51, both of which suggest that traditional multiple-based comparisons are currently inapplicable due to the lack of positive earnings and revenue data. In terms of trading range, the stock has a 52-week high of $356.00 and a 52-week low of $26.70, meaning the current share price sits within a highly volatile range that has experienced more than a tenfold expansion over the last year. The stock exhibits a Beta of 2.97, which signifies that the price volatility of PRAX is nearly three times that of the broader market, exposing investors to substantial swings in share price relative to general market movements.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, precluding any analysis of historical growth rates or comparisons between the expansion of earnings versus revenue since revenue figures are not currently available for calculation. As a non-dividend payer, the company maintains a Dividend Yield of N/A and a Payout Ratio of 0.0%, indicating that all available capital is retained and reinvested directly into research, development, and clinical trial expansion rather than distributed to shareholders. The absence of dividend payouts is a deliberate corporate strategy common in the clinical-stage sector, where management prioritizes funding high-risk, high-reward development programs over income generation for investors. Consequently, the overall growth and income profile for Praxis Precision Medicines is characterized by a focus on capital deployment for pipeline advancement rather than providing current income or demonstrating consistent earnings growth in the traditional sense.